CN104055852A - Traditional Chinese medicine composition for treating senile dementia and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating senile dementia and preparation method thereof Download PDFInfo
- Publication number
- CN104055852A CN104055852A CN201410307856.3A CN201410307856A CN104055852A CN 104055852 A CN104055852 A CN 104055852A CN 201410307856 A CN201410307856 A CN 201410307856A CN 104055852 A CN104055852 A CN 104055852A
- Authority
- CN
- China
- Prior art keywords
- total
- chinese medicine
- senile dementia
- parts
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating senile dementia and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition for treating senile dementia comprises, by weight, 10-30 parts of gynostemma total saponins, 5-20 parts of panax notoginseng saponins, 2-10 parts of ginseng total saponins, 2-10 parts of epimedium total flavonoids and 2-12 parts of mulberry total flavonoids. The traditional Chinese medicine can remarkably relieve dementia symptoms and learning and memory disorders of a model mouse with senile dementia. Meanwhile, generation and deposition of pathological products, namely, beta-amyloid protein closely related to senile dementia can be remarkably inhibited. In addition, the inhibition effect of the traditional Chinese medicine composition is remarkably superior to that of the positive medicine, namely, huperzine. Accordingly, the traditional Chinese medicine composition for treating senile dementia is remarkably improved and can be used for preparing more advanced medicine for preventing and treating senile dementia.
Description
Technical field
The present invention relates to technical field of Chinese medicines, be specifically related to a kind of Chinese medicine composition for the treatment of senile dementia and preparation method thereof.
Background technology
Senile dementia means and occurs in senile various chronic brain syndrome, comprise that Alzheimer (claims again presenile dementia, Alzheimer ' s disease, AD), vascular dementia (Vasculardementia, VD), Mixed dementia (AD+VD) and other dementias.First two is the main Types of alzheimer disease, accounts for the more than 90% of all dementias.AD is a kind of degeneration with brain, the dull-witted syndrome that brain cell atrophy is its pathologic basis.And VD is many, by ischemic, hemorrhagic apoplexy and hypoxia-induced cerebrovascular, caused.Mixed dementia (AD+VD) is common in old dementia patients, both pathology, symptom and neurobiochemistry feature are often interlaced overlapping, people had once done much work and had removed to differentiate AD and VD, but along with deepening continuously of research, similarity between the two and both may plyability in itself more and more be subject to people and pay attention to.They all show as clinically because of hypomnesis due to cognitive decrease, and behavior is slow, exercise not harmony.Its main pathological characters is in brain, occur a large amount of senile plaques, neurofibrillary tangles, amyloid-beta deposition and neuron vacuolar degeneration and lose in a large number.
Because alzheimer disease pathology change procedure is quite complicated, relate to the abnormal of multisystem, many target spots, although a large amount of man power and materials has been dropped in countries in the world in the research of finding the effective medicine of alzheimer disease, achievement is very limited.
Summary of the invention
In view of this, the object of the invention is to propose a kind of Chinese medicine composition for the treatment of senile dementia and preparation method thereof, to overcome the general not high defect of existing Chinese medicine or western medicine senile dementia obvious effective rate.
Based on above-mentioned purpose, the invention provides a kind of Chinese medicine composition for the treatment of senile dementia, described Chinese medicine composition is comprised of Herb Gynostemmae Pentaphylli total glycosides, Radix Notoginseng total arasaponins, Radix Ginseng total saponins, Herba Epimedii total flavones and Fructus Mori total flavones.
Preferably, described Chinese medicine composition consists of by weight ratio following raw material: 10～30 parts of Herb Gynostemmae Pentaphylli total glycosides, 5～20 parts of Radix Notoginseng total arasaponinss, 2～10 parts of Radix Ginseng total saponinss, 2～10 parts of Herba Epimedii total flavones and 2～12 parts of Fructus Mori total flavones.
Preferably, described Chinese medicine composition consists of by weight ratio following raw material: 18 parts of Herb Gynostemmae Pentaphylli total glycosides, 10 parts of Radix Notoginseng total arasaponinss, 4 parts of Radix Ginseng total saponinss, 4 parts of Herba Epimedii total flavones and 5 parts of Fructus Mori total flavones.
The present invention also provides a kind of method of preparing the Chinese medicine composition of above-mentioned treatment senile dementia, and described preparation method comprises:
1) extract Herb Gynostemmae Pentaphylli total glycosides: get Herb Gynostemmae Pentaphylli, cut off, add ethanol, heating extraction; By extracting solution sucking filtration, then filtrate decompression is concentrated, concentrated solution is centrifugal; Draw supernatant and cross macroporous resin, then use 60～80% ethanol elutions, collect eluent; It is 0.7～0.9 that eluent is evaporated to relative density, and then vacuum drying, obtains the solids that Herb Gynostemmae Pentaphylli total glycosides content is 90%～99%;
2) extract Radix Notoginseng total arasaponins: get Radix Notoginseng and pulverized, adding ethanol, heating extraction; By extracting solution sucking filtration, then filtrate decompression is concentrated, concentrated solution is centrifugal; Draw supernatant and cross macroporous resin, then use 60～80% ethanol elutions, collect eluent; It is 0.7～0.9 that eluent is evaporated to relative density, vacuum drying then, the solids that to obtain content of the total saponins in radix notoginseng be 90%～99%;
3) extract Radix Ginseng total saponins: get Radix Ginseng, section, adds ethanol, heating extraction; By extracting solution sucking filtration, then filtrate decompression is concentrated, concentrated solution is centrifugal; Draw supernatant and cross macroporous resin, then use 60～80% ethanol elutions, collect eluent; It is 0.7～0.9 that eluent is evaporated to relative density, vacuum drying then, the solids that to obtain total Ginsenosides Content be 90%～99%.
4) extract Herba Epimedii total flavones: get the stem and leaf of Herba Epimedii, cutting, adds ethanol, heating extraction; By extracting solution sucking filtration, then filtrate is concentrated into without ethanol taste; Be extracted with ethyl acetate concentrated solution, then extract is concentrated into without ethyl acetate taste; Finally, to cross macroporous resin without the concentrated solution of ethyl acetate taste, first use 8～15% ethanol elution impurity, 60～80% ethanol elution effective ingredient again, it is 0.7～0.9 that eluent is evaporated to relative density, then vacuum drying, obtains the solids that Herba Epimedii total flavones content is 75%～85%;
5) extract Fructus Mori total flavones: get Morus alba mulberry, add ethanol, heating extraction; By extracting solution sucking filtration, then filtrate is concentrated into without ethanol taste; Be extracted with ethyl acetate concentrated solution, then extract is concentrated into without ethyl acetate taste; Finally, will cross macroporous resin without the concentrated solution of ethyl acetate taste, first use 8～15% ethanol elution impurity, 60～80% ethanol elution effective ingredient again, it is 0.7～0.9 that eluent is evaporated to relative density, and then vacuum drying, obtains the solids that Fructus Mori general flavone content is 80%～89%;
6) by the described solids that contains Herb Gynostemmae Pentaphylli total glycosides, the solids that contains Radix Notoginseng total arasaponins, the solids that contains Radix Ginseng total saponins, the solids that contains Herba Epimedii total flavones and the solids that contains Fructus Mori total flavones according to certain part by weight proportioning mix homogeneously, obtain the Chinese medicine composition of described treatment senile dementia.
The present invention also provides a kind of medicine for the treatment of senile dementia, and described medicine is made by the Chinese medicine composition of above-mentioned treatment senile dementia and the pharmaceutic adjuvant of surplus.
Alternatively, the dosage form of described medicine is liquid preparation or solid preparation.
As can be seen from above, thing of the present invention can obviously improve Senlie dementia model mice dementia symptom Learning and Memory obstacle, can obviously suppress to occur with senile dementia generation and the deposition of closely related pathological product amyloid-beta, and this inhibitory action is obviously better than positive drug huperzine A simultaneously.The Chinese medicine composition for the treatment of senile dementia provided by the invention has obvious progressive as can be seen here, can be used for the medicine of the more advanced senile dementia prevention and cure of preparation.
The specific embodiment
For making the object, technical solutions and advantages of the present invention clearer, below in conjunction with specific embodiment, the present invention is described in more detail.
The Chinese medicine composition for the treatment of senile dementia provided by the invention is by Herb Gynostemmae Pentaphylli total glycosides (Gypenosides, Gyp), Radix Notoginseng total arasaponins (Panax notoginseng saponins, PNS), Radix Ginseng total saponins (Ginsenosides, Gin), Herba Epimedii total flavones (Total flavonoids of epimedium, TFE) and Fructus Mori total flavones (Total flavonoids of Mulberry, TFM) form.
As one embodiment of the present of invention, the Chinese medicine composition of described treatment senile dementia consists of by weight ratio following raw material: 18 parts of Herb Gynostemmae Pentaphylli total glycosides, 10 parts of Radix Notoginseng total arasaponinss, 4 parts of Radix Ginseng total saponinss, 4 parts of Herba Epimedii total flavones and 5 parts of Fructus Mori total flavones.
As one embodiment of the present of invention, the Chinese medicine composition of described treatment senile dementia consists of by weight ratio following raw material: 10 parts of Herb Gynostemmae Pentaphylli total glycosides, 16 parts of Radix Notoginseng total arasaponinss, 7.2 parts of Radix Ginseng total saponinss, 2.2 parts of Herba Epimedii total flavones and 7.5 parts of Fructus Mori total flavones.
As one embodiment of the present of invention, the Chinese medicine composition of described treatment senile dementia consists of by weight ratio following raw material: 24 Herb Gynostemmae Pentaphylli total glycosides, 8 parts of Radix Notoginseng total arasaponinss, 4.5 parts of Radix Ginseng total saponinss, 3 parts of Herba Epimedii total flavones and 11 parts of Fructus Mori total flavones.
As one embodiment of the present of invention, the Chinese medicine composition of described treatment senile dementia consists of by weight ratio following raw material: 15 parts of Herb Gynostemmae Pentaphylli total glycosides, 5 parts of Radix Notoginseng total arasaponinss, 9.5 parts of Radix Ginseng total saponinss, 6 parts of Herba Epimedii total flavones and 3.8 parts of Fructus Mori total flavones.
It should be noted that the active effective ingredient that described Herb Gynostemmae Pentaphylli total glycosides is Herb Gynostemmae Pentaphylli can be extracted and be obtained by Herb Gynostemmae Pentaphylli.Described Radix Notoginseng total arasaponins is the active active ingredient that Radix Notoginseng is extracted, and can be extracted and be obtained by Radix Notoginseng.Described Radix Ginseng total saponins is the active active ingredient of Radix Ginseng, can be extracted and be obtained by Radix Ginseng.Described Herba Epimedii total flavones is the active active ingredient of Herba Epimedii, can be extracted and be obtained by Herba Epimedii.The active effective ingredient that described Fructus Mori total flavones is Fructus Mori, can be extracted and be obtained by Fructus Mori.
The present invention also provides the preparation method of the Chinese medicine composition of described treatment senile dementia, and as one embodiment of the present of invention, described preparation method comprises:
1) extract Herb Gynostemmae Pentaphylli total glycosides: get the stem and leaf of Herb Gynostemmae Pentaphylli, be cut into the long segment of about 2cm, add 70% ethanol, 90 ℃ of water-bath reflux, extract, 3 times, each quality that adds ethanol is 8 times of Herb Gynostemmae Pentaphylli quality, extracts 1 hour at every turn; After merge extractive liquid,, by extracting solution sucking filtration, then concentrate filtrate to 0.5mg/mL, concentrated solution is centrifugal; Draw supernatant and cross macroporous resin (HPD-700 type), wash with water to the aobvious Molish reaction of effluent, then to use 70% ethanol elution, coutroi velocity be 3mL/min, collect eluent; Eluent is evaporated to relative density and is about 0.80 left and right (60 ℃ of mensuration), then vacuum drying, obtains the solids that Herb Gynostemmae Pentaphylli total glycosides content is 90%～99%.
2) extract Radix Notoginseng total arasaponins: get the underground tuber of Radix Notoginseng and pulverized, crossing 8 mesh sieves; Then add 60% ethanol, 90 ℃ of water-bath reflux, extract, 3 times, each quality that adds ethanol is 8 times of Radix Notoginseng quality, extracts 1.5 hours at every turn; After merge extractive liquid,, by extracting solution sucking filtration, then concentrate filtrate to 0.5mg/mL, concentrated solution is centrifugal; Draw supernatant and cross macroporous resin (HPD-700 type), wash with water to the not aobvious Molish reaction of effluent, then use 70% ethanol elution, flow velocity is 4mL/min, collects eluent; Eluent is evaporated to relative density and is about 0.80 left and right (60 ℃ of mensuration), vacuum drying then, the solids that to obtain content of the total saponins in radix notoginseng be 90%～99%.
3) extract Radix Ginseng total saponins: get Radix Ginseng underground rhizome, be cut into the thin slice that thickness is 1mm, add 70% ethanol, 90 ℃ of water-bath reflux, extract, 3 times, each quality that adds ethanol is Ginseng Quality 10 times, extract 1 hour at every turn; After merge extractive liquid,, by extracting solution sucking filtration, then concentrate filtrate to 0.45mg/mL, concentrated solution is centrifugal; Draw supernatant and cross macroporous resin (HPD-700 type), wash with water to the not aobvious Molish reaction of effluent, then use 70% ethanol elution, flow velocity is 3.5mL/min, collects eluent; Eluent is evaporated to relative density and is about 0.80 left and right (60 ℃ of mensuration), vacuum drying then, the solids that to obtain total Ginsenosides Content be 90%～99%.
4) extract Herba Epimedii total flavones: get the stem and leaf of Herba Epimedii, be cut into the long segment of about 2cm, add 75% ethanol, 85 ℃ of water-bath reflux, extract, 3 times, each quality that adds ethanol is 8 times of Herba Epimedii quality, extracts 1 hour at every turn; After merge extractive liquid,, by extracting solution sucking filtration, then filtrate is concentrated into without ethanol taste; Be extracted with ethyl acetate concentrated solution 2 times, then extract is concentrated into without ethyl acetate taste.Finally, to cross DM130 macroporous resin without the concentrated solution of ethyl acetate taste, first use 10% ethanol elution impurity, then 70% ethanol elution effective ingredient (in resin absorption process, sample solution mass concentration 0.5mg/mL, pH=4.5, absorption flow velocity 2.5mL/min, elution flow rate is 2.5mL/min), eluent is evaporated to relative density and is about 0.80 left and right (60 ℃ of mensuration), then vacuum drying, obtains the solids that Herba Epimedii total flavones content is 75%～85%.
5) extract Fructus Mori total flavones: get Morus alba mulberry, add 95% ethanol, 85 ℃ of water-bath reflux, extract, 3 times, each quality that adds ethanol is 9 times of Herba Epimedii quality, extracts 1 hour at every turn; After merge extractive liquid,, by extracting solution sucking filtration, then filtrate is concentrated into without ethanol taste; Be extracted with ethyl acetate concentrated solution 2 times, then extract is concentrated into without ethyl acetate taste.Finally, to cross HZ-801 macroporous resin without the concentrated solution of ethyl acetate taste, first use 10% ethanol elution impurity, then 75% ethanol elution effective ingredient (in resin absorption process, sample solution mass concentration 0.42mg/mL, pH=5, absorption flow velocity 3mL/min, elution flow rate is 3.5mL/min), eluent is evaporated to relative density and is about 0.80 left and right (60 ℃ of mensuration), then vacuum drying, obtains the solids that Fructus Mori general flavone content is 80%～89%.
6) by the solids that contains 90%～99% Herb Gynostemmae Pentaphylli total glycosides of said extracted, the solids that contains 90%～99% Radix Notoginseng total arasaponins, the solids that contains 90%～99% Radix Ginseng total saponins, the solids that contains 75%～85% Herba Epimedii total flavones and the solids that contains 80%～89% Fructus Mori total flavones according to certain part by weight proportioning mix homogeneously, obtain the Chinese medicine composition of described treatment senile dementia.
The impact of the Chinese medicine composition for the treatment of senile dementia provided by the invention on quick aging Model of Dementia mice SAMP8 learning memory disorder and brain A β 1-40, A β 1-42 expression
(1) laboratory animal and grouping
SAMP8 is quick aging Model of Dementia mice, by Japanese bamboo Tian Junnan professor, through 20 year modern age, prolonged to hand over to cultivate and form, life-span is about 12 months, the general feature of accelerated ageing that occurred at 4～6 months, possess the genetic background of homogeneous and stablize aging ill feature, its quick aging produces naturally, very similar to the gradual generation of clinical dementia, especially can form A β deposition at brain, and along with the age increases and expression increase.SAMR1 mice is the normal anti-Senescence-accelerated Mouse's of life process.These two kinds of mices are usually used in the research of senile dementia, and wherein SAMP8 mice is animal pattern, and SAMR1 is normal control animal.
50 of 6 monthly age SAMP8 mices are got in this research, are divided at random model group, positive controls (huperzine A), high dose group of the present invention, low dose group, and 10 every group, separately getting 10 of SAMR1 mices is Normal group.(animal credit number SCXK (capital) 2011-0012)
(2) administration: Animal adaptability is fed gastric infusion after 3 days.Gastric infusion (dosage is: high dose 250mg/kg of the present invention, low dosage 125mg/kg, positive control drug huperzine A 0.30mg/kg) after distilled water allotment for the Chinese medicine composition for the treatment of senile dementia provided by the invention and huperzine A.Normal group and model group give isometric distilled water, all gastric infusion (ig).Administration capacity is 0.1mL/10g, administration every day 1 time, successive administration 60d.Carry out subsequently Morris determined with Morris water Learning and Memory situation.
(3) mice learning and memory performances test: adopt the test of Morris water maze test.Water maze is a round pool, diameter 120cm, and high 50cm, depth of water 30cm, water temperature remains on 26 ± 1 ℃.Pond is divided into 4 quadrants, at quadrant 3 centers, place a platform, platform is circular, diameter is 11cm, platform is high is 29cm (be platform lower than water surface 1cm, claim to hide platform), and directly over labyrinth, 2m eminence is equipped with a miniature camera, and be connected with monitor with the videocorder in another room, record swimming track and the swimming time of mice.From the 2nd day to the 6th day test result of training, test altogether 5 days.Every natural gift two time periods of morning and afternoon, every Mus training of each time period 4 times, mice place of entry is all quadrants pool wall mid point, mice is put into pond towards pool wall by 4 people's water spots, survey and in its 60s, successfully move into platform (mice is found platform and is detained 5s on it and successfully moves into) required time (being escape latency).As mice in 60s can not successfully be moved into platform, experimenter is drawn upper mounting plate and makes it stop 10s, and recording escape latency is 60s.
(4) SABC detects mouse brain A β 1-40, A β 1-42 expression
After the memory of determined with Morris water animal finishes with behavior, de-cervical vertebra is put to death mice, removes braincap, takes out complete cerebral tissue, with fixing containing 4% paraformaldehyde.Pathological section, the dyeing of employing immunohistochemical method, around choosing at random Senescence-accelerated Mouse's quader cortex, Hippocampus, continuous five visuals field of white matter are observed under high power microscope, and count the mean number of A β 1-40 under five visuals field, A β 1-42 immuning positive cell.
(5) experimental result
As can be seen from Table 1, the escape latency of model group SAMP8 mice and other are respectively organized obvious prolongation (P<0.01), model group SAMP8 mice is on average sought number of times and is all obviously less than other each administration group mices (P<0.05), this shows that SAMP8 mouse model is successful, through after Drug therapy, thing of the present invention improves significantly to the learning and memory behavioral competence of senile dementia mice.The results are shown in Table 1.
Table 1 is respectively organized the population mean comparison in 5 days of novel water maze behavioristics relevant parameter
Note: compare * P < 0.05, * * P < 0.01 with SAMP8 model group
As can be seen from Table 2, model group mice SAMP8 and normal group mice SAMR1 comparison, model group mouse brain A β 1-40 and A β 1-42 immuning positive neuron number be obviously rising (P<0.01) all.With model group comparison, each treatment group mouse brain A β 1-40 and A β 1-42 immuning positive neuron number all obviously reduce (P<0.05 or P<0.01), mouse brain A β 1-40 and the A β 1-42 immuning positive neuron number of high dose group of the present invention and low dose group are all starkly lower than positive drug huperzine A group (P<0.01) simultaneously, this shows that the Chinese medicine composition for the treatment of senile dementia provided by the invention produces deposition to Senlie dementia model mouse brain amyloid-beta and has obvious inhibitory action, and this inhibitory action is obviously better than positive drug huperzine A.The results are shown in Table 2.
Table 2 A β 1-40, each group of A β 1-42 immuning positive neuron number of cells are relatively
Note: with model group comparison, * P<0.05, * * P<0.01; With huperzine A comparison,
▲p<0.05,
▲ ▲p<0.01
When 4 monthly age, there is significantly baiting situation in quick aging Model of Dementia mice SAMP8, ability of learning and memory with monthly age Normal group mice SAMR1, relatively there is serious obstacle.Oral administration gave the Chinese medicine composition for the treatment of senile dementia provided by the invention after 60 days, and obvious improvement has appearred in ability of learning and memory.Visible the present invention has the effect that improves dementia memory dysfunction.
During 4 monthly age, in quick aging Model of Dementia mice SAMP8 brain, A β 1-40, A β 1-42 immunohistochemical staining positive cell number are apparently higher than Normal group SAMR1 mice; When giving the Chinese medicine composition for the treatment of senile dementia provided by the invention, intervene after 60 days, administration group SAMP8 mouse brain A β 1-40, A β 1-42 immunohistochemical staining positive cell number are starkly lower than model control group mice.Visible the present invention has the Model of Dementia of inhibition mice SAMP8 brain amyloid-beta and produces and deposition, can be used for the medicine that preparation prevents and treats dementia.
The present invention also provides a kind of medicine for the treatment of senile dementia, and described medicine is made by pharmaceutical excipient or the pharmaceutic adjuvant of above-mentioned Chinese medicine composition and surplus.The dosage form of described medicine comprises liquid preparation or solid preparation.The administering mode of described medicine comprises oral administration or drug administration by injection.
In sum, thing of the present invention can obviously improve Senlie dementia model mice dementia symptom Learning and Memory obstacle, can obviously suppress to occur with senile dementia generation and the deposition of closely related pathological product amyloid-beta, and this inhibitory action is obviously better than positive drug huperzine A simultaneously.The Chinese medicine composition for the treatment of senile dementia provided by the invention has obvious progressive as can be seen here, can be used for the medicine of the more advanced senile dementia prevention and cure of preparation.
Those of ordinary skill in the field are to be understood that: the foregoing is only specific embodiments of the invention; be not limited to the present invention; within the spirit and principles in the present invention all, any modification of making, be equal to replacement, improvement etc., within all should being included in protection scope of the present invention.
Claims (6)
1. a Chinese medicine composition for the treatment of senile dementia, is characterized in that, described Chinese medicine is comprised of Herb Gynostemmae Pentaphylli total glycosides, Radix Notoginseng total arasaponins, Radix Ginseng total saponins, Herba Epimedii total flavones and Fructus Mori total flavones.
2. the Chinese medicine composition for the treatment of senile dementia according to claim 1, it is characterized in that, described Chinese medicine consists of by weight ratio following raw material: 10～30 parts of Herb Gynostemmae Pentaphylli total glycosides, 5～20 parts of Radix Notoginseng total arasaponinss, 2～10 parts of Radix Ginseng total saponinss, 2～10 parts of Herba Epimedii total flavones and 2～12 parts of Fructus Mori total flavones.
3. the Chinese medicine composition for the treatment of senile dementia according to claim 2, it is characterized in that, described Chinese medicine consists of by weight ratio following raw material: 18 parts of Herb Gynostemmae Pentaphylli total glycosides, 10 parts of Radix Notoginseng total arasaponinss, 4 parts of Radix Ginseng total saponinss, 4 parts of Herba Epimedii total flavones and 5 parts of Fructus Mori total flavones.
4. according to the preparation method of the Chinese medicine composition of the treatment senile dementia described in any one in claim 1～3, it is characterized in that, described preparation method is:
1) extract Herb Gynostemmae Pentaphylli total glycosides: get Herb Gynostemmae Pentaphylli, cut off, add ethanol, heating extraction; By extracting solution sucking filtration, then filtrate decompression is concentrated, concentrated solution is centrifugal; Draw supernatant and cross macroporous resin, then use 60～80% ethanol elutions, collect eluent; It is 0.7～0.9 that eluent is evaporated to relative density, and then vacuum drying, obtains the solids that Herb Gynostemmae Pentaphylli total glycosides content is 90%～99%;
2) extract Radix Notoginseng total arasaponins: get Radix Notoginseng and pulverized, adding ethanol, heating extraction; By extracting solution sucking filtration, then filtrate decompression is concentrated, concentrated solution is centrifugal; Draw supernatant and cross macroporous resin, then use 60～80% ethanol elutions, collect eluent; It is 0.7～0.9 that eluent is evaporated to relative density, vacuum drying then, the solids that to obtain content of the total saponins in radix notoginseng be 90%～99%;
3) extract Radix Ginseng total saponins: get Radix Ginseng, section, adds ethanol, heating extraction; By extracting solution sucking filtration, then filtrate decompression is concentrated, concentrated solution is centrifugal; Draw supernatant and cross macroporous resin, then use 60～80% ethanol elutions, collect eluent; It is 0.7～0.9 that eluent is evaporated to relative density, vacuum drying then, the solids that to obtain total Ginsenosides Content be 90%～99%.
4) extract Herba Epimedii total flavones: get the stem and leaf of Herba Epimedii, cutting, adds ethanol, heating extraction; By extracting solution sucking filtration, then filtrate is concentrated into without ethanol taste; Be extracted with ethyl acetate concentrated solution, then extract is concentrated into without ethyl acetate taste; Finally, to cross macroporous resin without the concentrated solution of ethyl acetate taste, first use 8～15% ethanol elution impurity, 60～80% ethanol elution effective ingredient again, it is 0.7～0.9 that eluent is evaporated to relative density, then vacuum drying, obtains the solids that Herba Epimedii total flavones content is 75%～85%;
5) extract Fructus Mori total flavones: get Morus alba mulberry, add ethanol, heating extraction; By extracting solution sucking filtration, then filtrate is concentrated into without ethanol taste; Be extracted with ethyl acetate concentrated solution, then extract is concentrated into without ethyl acetate taste; Finally, will cross macroporous resin without the concentrated solution of ethyl acetate taste, first use 8～15% ethanol elution impurity, 60～80% ethanol elution effective ingredient again, it is 0.7～0.9 that eluent is evaporated to relative density, and then vacuum drying, obtains the solids that Fructus Mori general flavone content is 80%～89%;
6) by the described solids that contains Herb Gynostemmae Pentaphylli total glycosides, the solids that contains Radix Notoginseng total arasaponins, the solids that contains Radix Ginseng total saponins, the solids that contains Herba Epimedii total flavones and the solids that contains Fructus Mori total flavones according to certain part by weight proportioning mix homogeneously, obtain the Chinese medicine composition of described treatment senile dementia.
5. a medicine for the treatment of senile dementia, is characterized in that, described medicine is made by the Chinese medicine composition for the treatment of senile dementia described in any one in claim 1～3 and the pharmaceutic adjuvant of surplus.
6. the medicine for the treatment of senile dementia according to claim 5, is characterized in that, the dosage form of described medicine is liquid preparation or solid preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410307856.3A CN104055852B (en) | 2014-06-30 | 2014-06-30 | Chinese medicine composition for the treatment of senile dementia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410307856.3A CN104055852B (en) | 2014-06-30 | 2014-06-30 | Chinese medicine composition for the treatment of senile dementia and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104055852A true CN104055852A (en) | 2014-09-24 |
| CN104055852B CN104055852B (en) | 2016-04-13 |
Family
ID=51543971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410307856.3A Active CN104055852B (en) | 2014-06-30 | 2014-06-30 | Chinese medicine composition for the treatment of senile dementia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104055852B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1386517A (en) * | 2001-05-17 | 2002-12-25 | 济南市中心医院 | Medicine for treating Parkinson's disease and its preparing process |
| CN1663607A (en) * | 2003-12-31 | 2005-09-07 | 赵恒� | Antisenescence medicine |
| CN101473943A (en) * | 2008-12-12 | 2009-07-08 | 广西中医学院 | Health-care food for improving memory function and preparation method thereof |
-
2014
- 2014-06-30 CN CN201410307856.3A patent/CN104055852B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1386517A (en) * | 2001-05-17 | 2002-12-25 | 济南市中心医院 | Medicine for treating Parkinson's disease and its preparing process |
| CN1663607A (en) * | 2003-12-31 | 2005-09-07 | 赵恒� | Antisenescence medicine |
| CN101473943A (en) * | 2008-12-12 | 2009-07-08 | 广西中医学院 | Health-care food for improving memory function and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104055852B (en) | 2016-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baatar et al. | Anti-inflammatory effect of ginsenoside Rh2-mix on lipopolysaccharide-stimulated RAW 264.7 murine macrophage cells | |
| Ren et al. | Neural regeneration: role of traditional Chinese medicine in neurological diseases treatment | |
| US11125130B2 (en) | Medicinal composition of extract of seed of Emblica officinalis and method of preparing the same | |
| CN105943888B (en) | Traditional Chinese medicine composition for improving memory and mild cognitive impairment and preparation method thereof | |
| Wang et al. | Progress in traditional Chinese medicine and natural extracts for the treatment of lupus nephritis | |
| CN104840527A (en) | Composition containing tenuifoliside and ginsenoside | |
| WO2021093087A1 (en) | Traditional chinese medicine composition having effect of improving cognition, preparation method therefor, and traditional chinese medicine preparation | |
| WO2012025010A1 (en) | Pharmaceutical composition for treating chronic liver disease and use thereof | |
| CN111407853B (en) | Traditional Chinese medicine composition for treating Parkinson's disease and preparation method thereof | |
| CN104543192A (en) | Lung-moistening tea and preparation method thereof | |
| CN101468155A (en) | Chinese medicinal composition for treating dementia, as well as preparation method, preparation and use thereof | |
| CN104055852B (en) | Chinese medicine composition for the treatment of senile dementia and preparation method thereof | |
| CN105943545B (en) | A kind of pharmaceutical composition and its purposes for improving memory disorders | |
| CN108514582A (en) | A kind of component compatibility Chinese medicine of prevention Alzheimer disease | |
| CN102293847B (en) | Chinese medicinal composition for treating constipation, acne and hyperlipidemia, and preparation method | |
| US20170035823A1 (en) | Method for treating or suppressing degenerative brain diseases by chinese herbal medicine composition | |
| CN101224247B (en) | Chinese traditional medicine compounds for treating Alzheimer's disease and preparing method thereof | |
| CN108295168B (en) | Traditional Chinese medicine composition for treating post-stroke depression | |
| CN103417664B (en) | Application of fructus ziziphi jujubae in preparing medicine or health-care product for treating Alzheimer disease | |
| CN115590935B (en) | Preparation and composition of Naolingdan and application of Naolingdan in medicines for preventing and intervening Alzheimer disease | |
| CN112057518A (en) | Traditional Chinese medicine composition for treating senile dementia and extraction method and application thereof | |
| CN104130232B (en) | The method of purification of a kind of EGCG and the EGCG of acquisition and pharmaceutical composition | |
| CN111569008B (en) | A pharmaceutical composition for treating neurodegenerative diseases | |
| CN104739949A (en) | Composition for treating Parkinson disease and preparation method of composition | |
| CN108837045A (en) | A kind of preparation method for paediatric acute tonsillitis, the Chinese medicine composition of acpuei pharyngitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |